Press Releases

March 15, 2018
— Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan , becoming the first IBAT inhibitor approved in the world — — ~$200 million current cash balance expected to be sufficient to fund operations into 2021 — — Management to host conference
January 25, 2018
BOSTON , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,970,000 shares of its common stock